FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367305282> ?p ?o ?g. }

• W4367305282 abstract "<h3>Objective:</h3> To explore the experience of neck pain (NP) among people with episodic migraine (EM) across migraine phases. <h3>Background:</h3> NP has been documented as a migraine symptom that is associated with increased disability. However, there are limited data on the experience of NP from the perspective of individuals with migraine. <h3>Design/Methods:</h3> A targeted PubMed literature review evaluated the relationship between NP and EM. Adults with clinician-diagnosed EM (5–14 days/month) were recruited to participate in concept elicitation interviews. Trained researchers used a semi-structured interview guide based on findings from the literature review. Open-ended questions were asked to elicit spontaneous reports of the NP experience associated with migraine and its temporal occurrence. Targeted questions were used if concepts were not raised spontaneously. <h3>Results:</h3> Findings from the literature review demonstrated that NP is highly prevalent before, during, and after the headache phase of migraine and was associated with increased Neck Disability Index score. Twenty participants completed the qualitative interviews; 13 (65.0%) reported NP related to migraine (pre-headache [n=12]; during headache [n=13]; post-headache [n=6]). Duration of NP ranged from a few hours to 1 day. NP was reported as the most bothersome symptom by 2 (10.0%) participants. Most participants described their NP as “tense,” “stiff,” or “tight” (n=8; 61.5%); others described their NP as a “dull ache” (n=4; 30.8%), a “kink” or “pulled muscle” (n=3; 23.1%), “sore” (n=2; 15.4%), or a “shooting pain” (n=1; 7.7%). <h3>Conclusions:</h3> Most participants reported NP associated with migraine. NP occurred before, during, and/or after the headache phase, and was predominantly described as “tense,” “stiff,” or “tight.” These results confirm that NP is a bothersome symptom for individuals with EM and may be an important outcome of effective treatment. <b>Disclosure:</b> Dr. Blumenfeld has received personal compensation for serving as an employee of The Neurology Center of Southern California. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Allergan. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Best Doctors. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GLG. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Blumenfeld has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Allergan. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Teva. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Lilly. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Ms. Mordin has received personal compensation for serving as an employee of RTI Health Solutions. Ms. KOSA has received personal compensation for serving as an employee of RTI International. Ms. Castro has received personal compensation for serving as an employee of RTI Health Solutions. Jonathan Stokes has received personal compensation for serving as an employee of AbbVie. Jonathan Stokes has received stock or an ownership interest from AbbVie. Ms. Shah has received personal compensation for serving as an employee of AbbVie. Ms. Shah has stock in AbbVie Inc. An immediate family member of Ms. Shah has received research support from National Institutes of Health. Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Collegium. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen." @default.
• W4367305282 created "2023-04-29" @default.
• W4367305282 creator A5000860251 @default.
• W4367305282 creator A5002788197 @default.
• W4367305282 creator A5009044802 @default.
• W4367305282 creator A5012694375 @default.
• W4367305282 creator A5024044218 @default.
• W4367305282 creator A5043410223 @default.
• W4367305282 creator A5050252532 @default.
• W4367305282 date "2023-04-25" @default.
• W4367305282 modified "2023-09-29" @default.
• W4367305282 title "Exploring the Experience of Neck Pain in Individuals With Episodic Migraine (P3-12.004)" @default.
• W4367305282 doi "https://doi.org/10.1212/wnl.0000000000202041" @default.
• W4367305282 hasPublicationYear "2023" @default.
• W4367305282 type Work @default.
• W4367305282 citedByCount "0" @default.
• W4367305282 crossrefType "proceedings-article" @default.
• W4367305282 hasAuthorship W4367305282A5000860251 @default.
• W4367305282 hasAuthorship W4367305282A5002788197 @default.
• W4367305282 hasAuthorship W4367305282A5009044802 @default.
• W4367305282 hasAuthorship W4367305282A5012694375 @default.
• W4367305282 hasAuthorship W4367305282A5024044218 @default.
• W4367305282 hasAuthorship W4367305282A5043410223 @default.
• W4367305282 hasAuthorship W4367305282A5050252532 @default.
• W4367305282 hasConcept C118552586 @default.
• W4367305282 hasConcept C142724271 @default.
• W4367305282 hasConcept C1862650 @default.
• W4367305282 hasConcept C187212893 @default.
• W4367305282 hasConcept C204787440 @default.
• W4367305282 hasConcept C2778541695 @default.
• W4367305282 hasConcept C2781038967 @default.
• W4367305282 hasConcept C71924100 @default.
• W4367305282 hasConceptScore W4367305282C118552586 @default.
• W4367305282 hasConceptScore W4367305282C142724271 @default.
• W4367305282 hasConceptScore W4367305282C1862650 @default.
• W4367305282 hasConceptScore W4367305282C187212893 @default.
• W4367305282 hasConceptScore W4367305282C204787440 @default.
• W4367305282 hasConceptScore W4367305282C2778541695 @default.
• W4367305282 hasConceptScore W4367305282C2781038967 @default.
• W4367305282 hasConceptScore W4367305282C71924100 @default.
• W4367305282 hasLocation W43673052821 @default.
• W4367305282 hasOpenAccess W4367305282 @default.
• W4367305282 hasPrimaryLocation W43673052821 @default.
• W4367305282 hasRelatedWork W1999055109 @default.
• W4367305282 hasRelatedWork W2052715550 @default.
• W4367305282 hasRelatedWork W2314379710 @default.
• W4367305282 hasRelatedWork W2414596196 @default.
• W4367305282 hasRelatedWork W2782801224 @default.
• W4367305282 hasRelatedWork W3099154545 @default.
• W4367305282 hasRelatedWork W3213155301 @default.
• W4367305282 hasRelatedWork W4210352011 @default.
• W4367305282 hasRelatedWork W4322723485 @default.
• W4367305282 hasRelatedWork W88926003 @default.
• W4367305282 isParatext "false" @default.
• W4367305282 isRetracted "false" @default.
• W4367305282 workType "article" @default.